Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19

被引:2
作者
Yang, Hui [1 ,2 ]
Yu, Xin [1 ,3 ]
Hou, Wenjing [2 ,4 ]
Liu, Xiangduan [2 ,5 ]
Chen, Jiaojiao [6 ]
Zhang, Ying [1 ,3 ]
Wang, Ying [5 ]
Zhu, Ying [1 ]
Qian, Qing [2 ,7 ]
Ma, Kuifen [2 ,8 ]
An, Zhuoling [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Dept Pharm, Beijing, Peoples R China
[2] Natl Alliance Transplant Pharmacists, Hangzhou, Zhejiang, Peoples R China
[3] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Dept Pharm, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Friendship Hosp, Dept Pharm, Beijing, Peoples R China
[5] Henan Univ Tradit Chinese Med, Zhengzhou Peoples Hosp, Dept Pharm, Clin Coll 5, Zhengzhou, Peoples R China
[6] Yantai Yuhuangding Hosp, Yantai, Peoples R China
[7] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China
[8] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Clin Pharm, Hangzhou, Peoples R China
关键词
COVID-19; nirmatrelvir/ritonavir; kidney transplant; severe kidney dysfunction;
D O I
10.1128/aac.01384-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Transplant patients face an elevated risk of coronavirus disease 2019 (COVID-19) morbidity and mortality and commonly encounter renal dysfunction. Nirmatrelvir is primarily excreted through the kidneys. The dosage of nirmatrelvir/ritonavir (NR) needs to be adjusted according to the degree of renal function impairment. Nevertheless, NR is not recommended for patients with severe renal impairment (estimated glomerular filtration rate < 30 mL/min) due to a dearth of associated research. In this study, we focus on kidney transplant patients and document and analyze the experiences of using NR in individuals with severe kidney dysfunction. This was a retrospective multicenter study that included transplant recipients hospitalized for COVID-19 in five major tertiary hospitals in China from December 2022 to June 2023. The outcomes consisted of the disease progression rate by day 28, individual disease progression events, safety outcomes, information on adverse events (AEs), and the blood drug concentrations of immunosuppressants. Data were presented with descriptive statistics. All analyses were performed using SPSS version 22. In total, 40 patients were included in the analysis. Considering the potential interaction between drugs, all patients temporarily discontinued their immunosuppressants during the NR treatment. None of the 32 moderate patients experienced disease progression. However, among the eight patients with critical COVID-19, unfortunately, two of them died. During the medication period, four patients experienced a total of six AEs associated with NR. None of them experienced AEs with a maximum grade of >= 3. Blood drug concentrations of immunosuppressants were monitored in 22 of 40 patients, and the blood drug concentrations of immunosuppressants did not show a significant increase, but some patients experienced lower blood drug concentrations. Our findings supported the use of NR therapy for the treatment of COVID-19 in transplant patients with severe renal insufficiency. A modified dose of NR was well-tolerated.
引用
收藏
页数:9
相关论文
共 18 条
[1]   Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir [J].
Badri, P. ;
Dutta, S. ;
Coakley, E. ;
Cohen, D. ;
Ding, B. ;
Podsadecki, T. ;
Bernstein, B. ;
Awni, W. ;
Menon, R. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (05) :1313-1322
[2]   Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus [J].
Banas, Bernhard ;
Kraemer, Bernhard K. ;
Krueger, Bernd ;
Kamar, Nassim ;
Undre, Nasrullah .
TRANSPLANTATION PROCEEDINGS, 2020, 52 (01) :102-110
[3]   Saving lives with nirmatrelvir/ritonavir one transplant patient at a time [J].
Belden, Katherine A. ;
Yeager, Sarah ;
Schulte, Jamie ;
Cantarin, Maria P. Martinez ;
Moss, Sean ;
Royer, Tricia ;
Coppock, Dagan .
TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (02)
[4]   Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019 (COVID-19) [J].
Chan, Gordon Chun Kau ;
Lui, Grace Chung Yan ;
Wong, Candy Ngai Sze ;
Yip, Sindy Sin Ting ;
Li, Timothy Chun Man ;
Cheung, Catherine Siu King ;
Sze, Ryan Kin Ho ;
Szeto, Cheuk Chun ;
Chow, Kai Ming .
CLINICAL INFECTIOUS DISEASES, 2023, 77 (10) :1406-1412
[5]   Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 [J].
Hammond, Jennifer ;
Leister-Tebbe, Heidi ;
Gardner, Annie ;
Abreu, Paula ;
Bao, Weihang ;
Wisemandle, Wayne ;
Baniecki, MaryLynn ;
Hendrick, Victoria M. ;
Damle, Bharat ;
Simon-Campos, Abraham ;
Pypstra, Rienk ;
Rusnak, James M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) :1397-1408
[6]   Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019 [J].
Hiremath, Swapnil ;
Blake, Peter G. ;
Yeung, Angie ;
McGuinty, Michaeline ;
Thomas, Doneal ;
Ip, Jane ;
Brown, Pierre Antoine ;
Pandes, Michael ;
Burke, Andrew ;
Sohail, Qazi Zain ;
To, Karen ;
Blackwell, Lindsay ;
Oliver, Matthew ;
Jain, Arsh K. ;
Chagla, Zain ;
Cooper, Rebecca .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (04) :485-490
[7]   A living WHO guideline on drugs for covid-19 [J].
Lamontagne, Francois ;
Agoritsas, Thomas ;
Macdonald, Helen ;
Leo, Yee-Sin ;
Diaz, Janet ;
Agarwal, Arnav ;
Appiah, John Adabie ;
Arabi, Yaseen ;
Blumberg, Lucille ;
Calfee, Carolyn S. ;
Cao, Bin ;
Cecconi, Maurizio ;
Cooke, Graham ;
Dunning, Jake ;
Geduld, Heike ;
Gee, Patrick ;
Manai, Hela ;
Hui, David S. ;
Kanda, Seema ;
Kawano-Dourado, Leticia ;
Kim, Yae-Jean ;
Kissoon, Niranjan ;
Kwizera, Arthur ;
Laake, Jon Henrik ;
Machado, Flavia R. ;
Qadir, Nida ;
Sarin, Rohit ;
Shen, Yinzhong ;
Zeng, Linan ;
Brignardello-Petersen, Romina ;
Lytvyn, Lyubov ;
Siemieniuk, Reed ;
Zeraatkar, Dena ;
Bartoszko, Jessica ;
Ge, Long ;
Maguire, Brittany ;
Rochwerg, Bram ;
Guyatt, Gordon ;
Vandvik, Per Olav .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 370
[8]   Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT) [J].
Lemaitre, Florian ;
Gregoire, Matthieu ;
Monchaud, Caroline ;
Bouchet, Stephane ;
Saint-Salvi, Beatrice ;
Polard, Elisabeth ;
Benaboud, Sihem ;
Chouchana, Laurent ;
Cracowski, Jean-Luc ;
Drici, Milou-Daniel ;
Garraffo, Rodolphe ;
Guilhaumou, Romain ;
Jonville-Bera, Annie-Pierre ;
Molimard, Mathieu ;
Muret, Patric ;
Peytavin, Gilles ;
Richard, Vincent ;
Solas, Caroline .
THERAPIE, 2022, 77 (05) :509-521
[9]   Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS [J].
Li, Meng ;
Zhang, Qing-Song ;
Liu, Xin-Ling ;
Wang, Hui-Ling ;
Liu, Wei .
PHARMACEUTICALS, 2022, 15 (12)
[10]   Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis [J].
Lingscheid, Tilman ;
Kinzig, Martina ;
Krueger, Anne ;
Mueller, Nils ;
Boelke, Georg ;
Tober-Lau, Pinkus ;
Muenn, Friederike ;
Kriedemann, Helene ;
Witzenrath, Martin ;
Sander, Leif E. ;
Soergel, Fritz ;
Kurth, Florian .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (11)